Overall rank by patents
#29,204
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 3 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A45C (PURSES; LUGGAGE; HAND CARRIED BAGS).
The verdict
Kanga holds 9 US patents across 3 technology areas, rank #29,204 of 50,000 tracked assignees.
Kanga, Llc has been granted 9 US utility patents between 2019 and 2025, placing Kanga, Llc at rank #29,204 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.4 claims per patent with primary concentration in A45C (PURSES; LUGGAGE; HAND CARRIED BAGS). As a US Corporation, Kanga, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Kanga sits between Kaleido Biosciences, Inc. (9 patents, rank #29,200) and Kiniksa Pharmaceuticals, Gmbh (9 patents, rank #29,208) - the closest US assignees by grant volume. The composite Innovation Score of 34.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 8 grants, compared with 1 in the 2015–2019 window, a +700% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Kanga, Llc's 5.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Kanga, Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Kaleido Biosciences, Inc.
9 patents
Kalt Maschinenbau AG
9 patents
Kammok Holdings, LLC
9 patents
Kane USA, Inc.
9 patents
Karl Storz Endoscopy-America, Inc.
9 patents
Kessler & Co. GmbH & Co. KG
9 patents
Kheiron Medical Technologies Ltd.
9 patents
Kiniksa Pharmaceuticals, GmbH
9 patents
Kanga, LLC
9 patents
What this shows Kanga holds 9 patents at rank #29,204, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #29,204 in granted patent volume.
Other assignees with the most granted patents in Kanga's primary technology class.
Kanga's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 54% higher than 46% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 11.1% |
| 2020 | 1 | 11.1% |
| 2023 | 2 | 22.2% |
| 2024 | 3 | 33.3% |
| 2025 | 2 | 22.2% |
Top 3 of 3 technology areas
Overall rank by patents
#29,204
Across all tracked assignees
34.0 out of 100
How to use this portfolio
Kanga's 9 grants land it in the top 54% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.